Skip to main content
Equibles
GANX logo

GANX · Gain Therapeutics, Inc.

Track GANX — free

Use GANX with AI

Ask our own analyst here, or connect this data to the AI you already use.

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

ChatGPT Claude Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$1.79 +0.02 (+1.13%) At close · Sep 2
Rebalance outlook locked
Going-concern doubt — flagged Aug 11, 2026

Substantial doubt about the company's ability to continue as a going concern.

“Our projected cash outflows for the upcoming periods raise substantial doubt about our ability to continue as a going concern for at least 12 months from the issuance of the financial statements included elsewhere in this Quarterly Report. We will need to raise additional capital to fund continued operations beyond the second quarter of 2027.”
View the 10-Q filed Aug 11, 2026
Market Cap
$77.90M
Shares
43.64M

GANX metrics

60 of 114 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$1.79
Market cap
$77.90M

Price action

19 metrics
Price change (1W)
-7.1%
Price change (30D)
+1.1%
Price change (3M)
-3.3%
Price change (6M)
-32.7%
Price change (YTD)
-45.0%
Price change (1Y)
-11.1%
Trailing year
Price change (5Y)
-77.4%
52-week high
$4.18
52-week low
$1.58
Change from 52-week high
-57.7%
Change from 52-week low
+12.0%
Annualized volatility
108.9%
Beta
1.8
RSI (14D)
42.7
Price vs SMA 50
-4.0%
Price vs SMA 200
-19.0%
Avg volume (3M)
798,352
Relative volume
0.3
Average dollar volume
$1.50M

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
43.64M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
1,200.0×
reciprocal yield 0.1%
EV / EBITDA
—
EV / EBIT
—
P / sales
1,411.8×
reciprocal yield 0.1%
P / book
6.9
reciprocal yield 14.5%
FCF yield
—
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-25.8%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
68.5×
reciprocal yield 1.5%
EV / revenue historical average (5Y)
68.5×
reciprocal yield 1.5%
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2026-03-23

Profitability

9 metrics
Gross margin
—
Operating margin
-40,328.3%
Trailing 12 months
Net margin
-40,354.3%
Gross profit (TTM)
—
Operating profit (TTM)
−$19.29M
Net income (TTM)
−$20.11M
Trailing 12 months
Diluted EPS (TTM)
$-0.50
FCF margin
—
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
$1.75

Growth

11 metrics
Revenue growth YoY
+22.6%
Year over year
Net income growth YoY
—
Revenue (TTM)
$55,180
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+41.3%
Year over year · more shares
Revenue CAGR (3Y)
+24.1%
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-178.1%
Return on assets
-130.4%
Debt / equity
0.0
Current ratio
4.4
EBITDA (TTM)
−$19.19M
Free cash flow (TTM)
—
Quick ratio
4.4
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Cash & equivalents
$13.08M
Total assets
$15.42M
Total debt
$343,686

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$18.95M
Capital expenditures (TTM)
—
R&D (TTM)
$10.10M
SG&A (TTM)
—
Stock compensation (TTM)
$1.83M
R&D / revenue
—
Stock compensation / revenue
—

Ownership (13F)

3 metrics
13F filers
49
13F filer change QoQ
+7
Institutional ownership
20.1%

Short interest

3 metrics
Short interest
6.8%
Latest settlement · 4.9 days to cover
Days to cover
4.9d
Short-squeeze score
57 / 100

Insider activity

2 metrics
Net insider buying (90D)
—
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
Flagged
Key facts CIK 1819411 CUSIP 36269B105 13F (30d) 42 filings 42 filers Visit website Investor relations

Report a Problem

Category
Description
Email (optional, for follow-up)